Skip to main content

Table 2 Comparison of characteristics between progression and non-progression patients during the follow-up

From: Time-averaged albumin predicts the long-term prognosis of IgA nephropathy patients who achieved remission

Characteristics

Remission patients

Non-progression patients

Progression patients

P-value

 

(n = 369)

(n = 308)

(n = 61)

 

ALB g/L at month 3

40.9 ± 4.9

41.3 ± 0.6

39.0 ± 1.7

NS

ALB g/L at month 6

42.9 ± 4.2

43.5 ± 0.6

40.5 ± 1.3

0.02

TA-ALB g/L

42.1 ± 3.8

42.7 ± 0.5

39.4 ± 1.2

0.01

SCr μmol/L at month 3

90.2 ± 35.5

82.7 ± 3.9

121.6 ± 13.9

0.01

SCr μmol/L at month 6

88.2 ± 37.5

80.3 ± 4.2

121.3 ± 14.1

0.002

TA-SCr μmol/L

91.8 ± 46.8

80.5 ± 4.2

136.7 ± 21.0

0.002

BUN mmol/L at month 3

7.4 ± 2.9

6.8 ± 0.3

9.8 ± 1.1

0.01

BUN mmol/L at month 6

6.5 ± 2.3

6.1 ± 0.3

8.0 ± 0.9

0.02

TA-BUN mmol/L

6.6 ± 2.2

6.1 ± 0.2

8.6 ± 0.9

0.004

eGFR (ml/min/1.73 m2) at month 3

85.5 ± 33.1

90.8 ± 4.4

63.4 ± 8.2

0.01

eGFR (ml/min/1.73 m2) at month 6

88.9 ± 33.7

95.1 ± 4.6

63.1 ± 7.8

0.003

TA-eGFR (ml/min/1.73 m2)

88.5 ± 33.2

95.1 ± 4.5

61.9 ± 8.1

0.002

UPE (g/d) at month 3

0.7 (0.4-1.3)

0.6 (0.2-1.0)

1.3 (0.7-2.0)

0.04

UPE (g/d) at month 6

0.4 (0.2-0.7)

0.4 (0.1-0.7)

0.4 (0.2-1.2)

NS

TA-UPE (g/d)

1.1 (0.6-1.6)

1.0 (0.6-1.4)

1.3 (1.0-2.1)

NS

  1. Values are given as means ± standard deviation (SD) if the variables had a normal distribution and as medians (IQR) if the variables did not have a normal distribution; n (%) was used for the categorical variables.
  2. TA-ALB: time-averaged serum albumin; TA-SCr: time-averaged serum creatinine; TA-BUN: time-averaged blood urea nitrogen; TA-eGFR: time-averaged eGFR; TA-UPE: time-averaged 24-h urinary protein excretion.